In cases of advanced non‐small cell lung cancer (NSCLC), testing for predictive biomarkers is recommended, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS proto‐oncogene 1 (ROS1), proto‐oncogene B‐raf (BRAF) V600E, neurotrophic tyrosine receptor kinase (NTRK) and RET fusions, MET exon 14 skipping alterations, and programmed death‐ligand 1 (PD‐L1) expression via immunohistochemistry (IHC) [8]. This evidence concerns the gene RET and non-small cell lung carcinoma.